Clinical Trials

Phase 1/2 Active not recruiting

Sarcoma, Ewing

NCT05099666 2026-04-13

Lurbinectedin + Doxorubicin In Leiomyosarcoma

62 enrolled

NCT05711615 2026-04-13

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

Phase 1 Recruiting

30 enrolled

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT07243626 2026-04-08

Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma

15 enrolled

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

350 enrolled

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT07477457 2026-03-17

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

45 enrolled

Neoplasm Metastasis, Osteosarcoma

NCT07194044 2026-03-16

METTSEO

Phase 1 Recruiting

15 enrolled

Sarcoma, Ewing

NCT01042379 2026-03-13

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06088290 2026-03-11

SaLuDo

Phase 3 Recruiting

450 enrolled

Phase 1/2 Not yet recruiting

Leiomyosarcoma, Neoplasms

NCT07460986 2026-03-10

BEXAR

278 enrolled

NCT05218499 2026-03-02

Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

Phase 2/3 Completed

400 enrolled 15 charts

Liposarcoma

NCT04199026 2026-02-19

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Phase NA Recruiting

20 enrolled

Phase 2/3 Active not recruiting

NCT06820957 2026-02-17

Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body

437 enrolled

Sarcoma, Ewing

NCT07125183 2026-02-05

Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

20 enrolled

Leiomyosarcoma, Sarcoma

NCT04028063 2026-01-27

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

65 enrolled

NCT06239272 2026-01-26

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Phase 1/2 Recruiting

139 enrolled

Plasma cellSarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

NCT01231906 2026-01-23

Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Phase 3 Completed

642 enrolled 11 charts

Phase 2 Not yet recruiting

Localized Extraskeletal Ewing Sarcoma

NCT05481645 2026-01-09

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Phase 2 Terminated

71 enrolled

GynecologicSarcoma

Advanced Endometrial Cancer

NCT07321912 2026-01-08

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

406 enrolled

Sarcoma, Ewing, Osteosarcoma

NCT06220032 2026-01-05

HO170DLBCL

Phase 3 Recruiting

324 enrolled

LymphoidSarcoma

Heart Failure, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating, Cardiotoxicity

NCT06835049 2025-12-30

TNT-HYPE

24 enrolled

Phase 1 Active not recruiting

Hyperthermia, Sarcoma

NCT01746238 2025-12-19

Bevacizumab/Doxorubicin/Radiation for Sarcoma

14 enrolled

NCT01871766 2025-12-17

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

115 enrolled

Phase 1 Not yet recruiting

Rhabdomyosarcoma

NCT07027423 2025-12-01

BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas

32 enrolled

NCT02811523 2025-11-26

In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma

Phase 1 Recruiting

17 enrolled

Bone Neoplasms, Sarcoma

NCT07049848 2025-11-20

SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma

50 enrolled

Phase 2 Not yet recruiting

NCT07231250 2025-11-19

Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

40 enrolled

Dendritic Cell Sarcoma, Interdigitating

NCT00077285 2025-11-04

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

65 enrolled

Malignant mesenchymal tumor, Rhabdomyosarcoma, Sarcoma

NCT03805022 2025-10-02

Tertiary Lymphoid Structures, Neoplasm Metastasis, Sarcoma

NCT04968106 2025-08-13

TORNADO

66 enrolled

NCT05858710 2025-07-28

Study of DPPG2-TSL-DOX Combined With Hyperthermia in Soft Tissue Sarcoma

Phase 1 Completed

8 enrolled

NCT01027910 2025-07-24

PCI-24781 in Combination With Doxorubicin to Treat Sarcoma

Phase 1/2 Completed

20 enrolled 10 charts

NCT06277154 2025-07-24

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

148 enrolled

GynecologicSarcoma

Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Endometrial Stromal, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

NCT02451943 2025-07-15

ANNOUNCE

Phase 3 Completed

509 enrolled 23 charts

Phase 2 Not yet recruiting

Leiomyosarcoma, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

NCT07034508 2025-06-24

A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

134 enrolled

Phase 3 Active not recruiting

Dendritic Cell Sarcoma, Interdigitating

NCT00470223 2025-06-08

OS2006

318 enrolled

Sarcoma, Osteosarcoma

NCT03719430 2025-04-29

APX005M and Doxorubicin in Advanced Sarcoma

27 enrolled

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Neurofibrosarcoma

NCT06268457 2025-04-02

Embodesmo

Recruiting

20 enrolled

Desmoid Tumors

NCT06524583 2025-03-30

L-UteCIN

198 enrolled

Leiomyosarcoma Uterus

NCT04757337 2025-03-25

GERICO14

Phase 3 Recruiting

214 enrolled

Phase EARLY_PHASE1 Terminated

NCT04213794 2025-02-20

TOASTIT

2 enrolled

GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Colonic Neoplasms, Fallopian Tube Neoplasms, Liposarcoma, Ovarian Neoplasms, Pelvic Neoplasms, Rectal Neoplasms, Rhabdomyosarcoma, Sarcoma, Stomach Neoplasms, Desmoplastic Small Round Cell Tumor

NCT05100628 2025-01-06

A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma

Phase 1 Terminated

9 enrolled 10 charts

NCT04996004 2024-12-11

TTI-621-03

Phase 2 Terminated

76 enrolled 53 charts

Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Dermatofibrosarcoma

NCT04055753 2024-12-04

Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma

Active not recruiting

24 enrolled